Laboratory for Molecular Design and Simulation (LMDS), Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
J Biomol Struct Dyn. 2020 Mar;38(5):1272-1282. doi: 10.1080/07391102.2019.1599427. Epub 2019 Apr 7.
Sclerostin, an antagonist of the Wnt/β-catenin signaling pathway, was discovered as a potential therapeutic target for stimulating bone formation in osteoporosis. In this study, molecular docking was employed to predict the binding of 29 herbal compounds, which were reported as bone formation stimulators, to the loop2 region of sclerostin. Then, the 50 ns molecular dynamics (MD) simulation of the complexes between sclerostin and the top 10 hits obtained from molecular docking were carried out. Root mean square deviations (RMSDs) analysis of MD trajectories pointed out that all ligands-complexes remain stable throughout the duration of MD simulations. In addition, the molecular mechanics/generalized born surface area (MM/GBSA) binding free energy and energy decomposition analyses were determined. The results here suggested that baicalin is the most promising inhibitor of sclerostin. Interestingly, baicalin binds to sclerostin via the hydrophobic interaction with the amino acid residues on loop2 region but outside the Pro-Asn-Ala-Ile-Gly (PNAIG) motif, particularly the Arg-Gly-Lys-Trp-Trp-Arg (RGKWWR) motif. This finding could be a novel strategy for developing new sclerostin inhibitors in the future.Communicated by Ramaswamy H. Sarma.
骨硬化蛋白(Sclerostin)是 Wnt/β-连环蛋白信号通路的拮抗剂,被发现是一种有潜力的治疗骨质疏松症中骨形成的靶点。在这项研究中,采用分子对接预测了 29 种被报道为骨形成刺激剂的草药化合物与骨硬化蛋白的环 2 区结合的情况。然后,对分子对接获得的前 10 个命中化合物与骨硬化蛋白的 50ns 分子动力学(MD)模拟复合物进行了模拟。MD 轨迹的均方根偏差(RMSD)分析表明,所有配体-复合物在整个 MD 模拟过程中都保持稳定。此外,还确定了分子力学/广义 Born 表面积(MM/GBSA)结合自由能和能量分解分析。结果表明,黄芩苷是最有前途的骨硬化蛋白抑制剂。有趣的是,黄芩苷通过与环 2 区域上的氨基酸残基的疏水相互作用与骨硬化蛋白结合,但不在 Pro-Asn-Ala-Ile-Gly(PNAIG)基序内,特别是 Arg-Gly-Lys-Trp-Trp-Arg(RGKWWR)基序内。这一发现可能为未来开发新的骨硬化蛋白抑制剂提供一种新策略。由 Ramaswamy H. Sarma 交流。